Should GLP-1 receptor agonist therapy be used to treat obesity in Bardet-Biedl syndrome?
Journal of Clinical Investigation · 2025
DOI: 10.1172/jci191822 ↗Kurz gefasst
Kommentar in der Zeitschrift Journal of Clinical Investigation, 2025. Verfasst von Jeremy W Tomlinson. Hauptthemen laut MEDLINE: Bardet-Biedl Syndrome, Obesity, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Zitieren
APA
Tomlinson, J. W. (2025). Should GLP-1 receptor agonist therapy be used to treat obesity in Bardet-Biedl syndrome?. Journal of Clinical Investigation. https://doi.org/10.1172/jci191822
Vancouver
Tomlinson JW. Should GLP-1 receptor agonist therapy be used to treat obesity in Bardet-Biedl syndrome?. Journal of Clinical Investigation. 2025. doi:10.1172/jci191822
BibTeX
@article{Tomlinson2025,
author = {Tomlinson, Jeremy W},
title = {Should GLP-1 receptor agonist therapy be used to treat obesity in Bardet-Biedl syndrome?},
journal = {Journal of Clinical Investigation},
year = {2025},
doi = {10.1172/jci191822}
}
EUVIMED